A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.

Gerald S. Falchook, Anthony J. Olszanski, James Strauss et al.|Journal of Clinical Oncology|2021

Cited by 10